Anthos’ detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer’s failed? Endpoints News Anthos spells out benefits…
Read More »Endpoints
GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk? Endpoints News Obesity drugs: huge study identifies…
Read More »